Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Releases Quarterly Earnings Results

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) released its earnings results on Tuesday, May 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.01), FiscalAI reports. Lineage Cell Therapeutics had a negative net margin of 434.44% and a negative return on equity of 89.36%. The company had revenue of $1.73 million during the quarter, compared to analyst estimates of $3.60 million.

Here are the key takeaways from Lineage Cell Therapeutics’ conference call:

• Management said OpRegen remains on track in a partner-run open-label GA study, citing expanded site activations and Roche/Genentech language describing the program as potentially disease-modifying. They also highlighted long-term data showing vision gains persisted for at least three years after a single dose in the target location.
• The company emphasized major progress at its AlloSCOPE manufacturing platform, which now supports multiple new programs and could enable low-cost, scalable cell production. Management said this platform is a key differentiator because it focuses on reproducible manufacturing before clinical testing.
• COR1, Lineage’s wholly owned corneal endothelial cell program, advanced into preclinical development after the team successfully manufactured off-the-shelf cells meeting internal identity, morphology, and function criteria. Management plans to move the program into translational studies and then initial human testing.
• The ILT1 diabetes initiative is progressing through scale-up work for undifferentiated pluripotent cells, with management reporting the first internal manufacturing milestone was met. The company stressed that the main risk is proving large-scale manufacturing and differentiation can work reliably, and that this remains a stepwise go/no-go process.
• ReSonance reached an important manufacturing milestone with three successful engineering runs and a new deafening model to support functional testing. Lineage also said its Demant partnership is progressing well and that it expects to move toward GMP material and eventual FDA discussions for human testing.
• Financially, Lineage ended the quarter with $53.4 million in cash, which it says funds operations into Q2 2028. First-quarter revenue rose to $1.7 million, while operating expenses increased to $9.3 million, contributing to a net loss of $4.8 million.

Lineage Cell Therapeutics Stock Performance

LCTX opened at $1.27 on Monday. The business’s fifty day moving average is $1.40 and its two-hundred day moving average is $1.59. The company has a market cap of $316.61 million, a price-to-earnings ratio of -4.38 and a beta of 1.53. Lineage Cell Therapeutics has a one year low of $0.69 and a one year high of $2.09.

Institutional Investors Weigh In On Lineage Cell Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in LCTX. Jump Financial LLC purchased a new position in Lineage Cell Therapeutics during the 2nd quarter valued at about $28,000. DLD Asset Management LP acquired a new position in shares of Lineage Cell Therapeutics during the 4th quarter worth approximately $33,000. Qube Research & Technologies Ltd acquired a new stake in Lineage Cell Therapeutics during the 2nd quarter valued at $35,000. Hudson Bay Capital Management LP acquired a new stake in shares of Lineage Cell Therapeutics during the second quarter valued at $44,000. Finally, Kestra Advisory Services LLC boosted its stake in shares of Lineage Cell Therapeutics by 174.7% during the 4th quarter. Kestra Advisory Services LLC now owns 27,747 shares of the company’s stock worth $46,000 after purchasing an additional 17,647 shares during the last quarter. 62.47% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Canaccord Genuity Group started coverage on shares of Lineage Cell Therapeutics in a research note on Tuesday, April 28th. They issued a “buy” rating and a $9.00 target price for the company. D. Boral Capital reissued a “buy” rating and issued a $3.00 price target on shares of Lineage Cell Therapeutics in a report on Monday, May 4th. B. Riley Financial lifted their price target on Lineage Cell Therapeutics from $3.00 to $4.00 and gave the company a “buy” rating in a research note on Wednesday, March 25th. Finally, HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Lineage Cell Therapeutics in a report on Tuesday, March 24th. Four investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $6.25.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.